Prot# C-1802: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety & Efficacy of Natalizumab, When Added to Avonex® (Interferon beta-1a), in Subjects w/ Relapsing-Remitting Multiple Sclerosis

Project: Research project

Project Details

StatusFinished
Effective start/end date3/21/02 → 4/2/07

Funding

  • Biogen, Inc. (legacy sponsor) (C-1802)